Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 30, 2015 6:15 AM ET

Biotechnology

Company Overview of Chelsea Therapeutics International Ltd.

Company Overview

Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It is developing Northera (droxidopa), a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH) in patients with primary autonomic failure, dopamine-ß-hydroxylase, and deficiency and non-diabetic autonomic neuropathy. The company is also evaluating droxidopa in other potentially norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, freezing of gait, and adult attention deficit hyperac...

3530 Toringdon Way

Suite 200

Charlotte, NC 28277

United States

Founded in 2002

19 Employees

Phone:

704-341-1516

Key Executives for Chelsea Therapeutics International Ltd.

Chief Financial Officer, Principal Accounting Officer and Vice President of Administration
Age: 62
Chief Scientific Officer and Vice President
Age: 61
Chief Medical Officer and Vice President
Age: 57
Chief Commercial Officer and Vice President
Age: 64
Vice President of Business Development
Age: 45
Compensation as of Fiscal Year 2015.

Chelsea Therapeutics International Ltd. Key Developments

Chelsea Therapeutics International Ltd.(NasdaqGM:CHTP) dropped from Russell 2000 Index

Chelsea Therapeutics International Ltd. will be removed from the Russell 2000 Index.

Chelsea Therapeutics International Ltd.(NasdaqGM:CHTP) dropped from Russell 3000 Index

Chelsea Therapeutics International Ltd. will be removed from the Russell 3000 Index.

Chelsea Therapeutics International Ltd.(NasdaqGM:CHTP) dropped from NASDAQ Composite Index

Chelsea Therapeutics International Ltd. will be removed from the NASDAQ Composite Index.

Similar Private Companies By Industry

Company Name Region
OlFactor Laboratories, Inc. United States
Elan Pharmaceutical Investments Ltd. United States
Embryo Armor Technologies, LLC United States
AbbVie Biotherapeutics Inc. United States
OncoCyte Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Chelsea Therapeutics International Ltd., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.